NVG-291

Medical Disclaimer: This article is for informational purposes only. It is not medical advice. NVG-291 is an experimental drug. It is still in clinical trials. It is not approved by the FDA. Do not try to buy or use this drug. Talk to your doctor before making any health decisions.

What Is NVG-291?

NVG-291 is a new medicine. It is being tested to help people with nerve damage. Your nerves are like electrical wires in your body. They carry messages from your brain to your muscles. When nerves get damaged, those messages stop getting through. This can happen in spinal cord injuries, Alzheimer's disease, and multiple sclerosis (MS).

NVG-291 is not a pill. It is a peptide. You can think of a peptide as a tiny protein. It is injected under the skin, like an insulin shot.

The company making it is called NervGen Pharma. They are based in Canada. Their stock trades on the Nasdaq under the symbol NGEN.

How Does It Work?

Imagine your nerves have a parking brake. When you are a baby, the brake is off. Your nerves can grow and repair themselves easily. That is how a baby learns to walk.

As you grow up, your body pulls the parking brake on. The brake is a protein called PTPσ (pronounced P-T-P-sigma). It tells your nerves: "Stop growing. We are done here." That brake is useful. It stops nerves from growing where they should not.

But when you get a spinal cord injury, or when you get a disease like Alzheimer's, you WANT those nerves to grow and repair. The brake is now a problem. It stops the healing.

NVG-291 releases the parking brake. It blocks PTPσ. With the brake off, the nerves can start repairing themselves again. This is a brand new idea. No other drug works this way.

Who Is It For?

Right now, NVG-291 is being tested for three conditions:

Spinal cord injury. This is the most advanced testing. Phase 2 is complete. People with chronic spinal cord injuries (injuries that happened years ago) showed improvements in walking and arm function.
Multiple sclerosis (MS). MS damages the protective coating around nerves. NVG-291 may help repair that coating.
Alzheimer's disease. Alzheimer's damages nerve connections in the brain. NVG-291 may help rebuild those connections.

Where Does It Stand?

Stage	Status
Lab Testing (Preclinical)	✅ Complete
Phase 1 (Safety in Humans)	✅ Complete
Phase 2 (Does It Work?)	✅ Complete — Positive Results
End-of-Phase 2 FDA Meeting	✅ Complete (April 2026)
Phase 3 (Large Confirmatory Trial)	⏳ RESTORE trial being planned (chronic tetraplegia)
FDA Approval	❌ Not yet

Why Does This Matter?

NVG-291 matters for two big reasons.

First, it is a completely new approach. Most drugs for nerve damage try to protect nerves from dying. NVG-291 does something different. It tells the surviving nerves to grow and reconnect. It unlocks a repair system that is already inside your body.

Second, it could help with many age-related diseases. As we age, our nerves lose the ability to repair themselves. That is part of why our memory gets worse. Why our balance gets shaky. Why we recover more slowly from injuries. A drug that flips the repair switch back on could change how we age.

If NVG-291 works in Phase 3, it would be the first drug to actually repair nerve damage, not just slow down the damage. That would be a historic moment in medicine.

What We Do Not Know Yet

Phase 3 could fail. Many drugs that look great in Phase 2 fail in Phase 3. The sample sizes are bigger. The bar is higher.
Side effects are not fully known. The parking brake exists for a reason. Turning it off everywhere in the body might cause problems we do not see in small trials. Unwanted nerve growth is a real risk.
It may not work for Alzheimer's. The Alzheimer's studies are very early. The brain is much more complicated than the spinal cord.
Timeline is long. Phase 3 trials take years. Even if everything goes perfectly, NVG-291 is still several years away from FDA approval.
NervGen is a small company. They may need more funding to finish Phase 3. They may partner with a larger drug company.

The Bottom Line

NVG-291 is the first drug designed to release the brakes on your body's own nerve repair system. Early results in spinal cord injury are encouraging. Phase 3 testing is being planned. If it works, it could change how we treat not just spinal cord injuries, but also Alzheimer's, MS, and age-related nerve decline. But it is still years away from approval, and Phase 3 is where most drugs fail. Watch this space.

Sources

NervGen Pharma. "NVG-291 Mechanism of Action." Official company website. nervgen.com
BioXconomy. "Breakthrough peptide repairs nerves after spinal cord injury in clinical trial." July 7, 2026.
Seeking Alpha. "NervGen Pharma: I Think The Biggest Risks Are Now Behind It." July 2, 2026.
Investing.com. "NervGen reports positive gait analysis data for NVG-291 trial." May 26, 2026.
NervGen Pharma. "NervGen Prepares RESTORE Phase 3 Trial in Chronic Tetraplegia With NVG-291." May 20, 2026.
NervGen Pharma. "Successful End-of-Phase 2 Meeting with FDA." April 7, 2026.
Case Western Reserve University. "How one researcher's legacy offers hope for spinal cord injuries." May 27, 2026.